Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Osteoporosis International
Erschienen in: Osteoporosis International 5/2015

01.05.2015 | Original Article

Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model

verfasst von: L. Si, T. M. Winzenberg, Q. Jiang, A. J. Palmer

Erschienen in: Osteoporosis International | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Summary

This study aimed to document and validate a new cost-effectiveness model of osteoporosis screening and treatment strategies. The state-transition microsimulation model demonstrates strong internal and external validity. It is an important tool for researchers and policy makers to test the cost-effectiveness of osteoporosis screening and treatment strategies.

Introduction

The objective of this study was to document and validate a new cost-effectiveness model of screening for and treatment of osteoporosis.

Methods

A state-transition microsimulation model using a lifetime horizon was constructed with seven Markov states (no history of fractures, hip fracture, vertebral fracture, wrist fracture, other fracture, postfracture state, and death) describing the most important clinical outcomes of osteoporotic fractures. Tracker variables were used to record patients’ history, such as fracture events, duration of treatment, and time since last screening. The model was validated for Chinese postmenopausal women receiving screening and treatment versus no screening. Goodness-of-fit analyses were performed for internal and external validation. External validity was tested by comparing life expectancy, osteoporosis prevalence rate, and lifetime and 10-year fracture risks with published data not used in the model.

Results

The model represents major clinical facets of osteoporosis-related conditions. Age-specific hip, vertebral, and wrist fracture incidence rates were accurately reproduced (the regression line slope was 0.996, R 2 = 0.99). The changes in costs, effectiveness, and cost-effectiveness were consistent with changes in both one-way and probabilistic sensitivity analysis. The model predicted life expectancy and 10-year any major osteoporotic fracture risk at the age of 65 of 19.01 years and 13.7 %, respectively. The lifetime hip, clinical vertebral, and wrist fracture risks at age 50 were 7.9, 29.8, and 18.7 % respectively, all consistent with reported data.

Conclusions

Our model demonstrated good internal and external validity, ensuring it can be confidently applied in economic evaluations of osteoporosis screening and treatment strategies.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Mithal A, Ebeling P, Kyer CS (2013) Asia-pacific regional audit: epidemiology, costs & burden of osteoporosis in 2013. International Osteoporosis Foundation, Nyon
3.
Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch osteoporos 8:136CrossRefPubMedCentralPubMed
4.
Watts JJ, Abimanyi-Ochom J, Sanders KM (2013) Osteoporosis costing all Australians: a new burden of disease analysis—2012 to 2022. Osteoporosis Australia
5.
Torrance GW, Drummond MF (2005) Methods for the economic evaluation of health care programmes. Oxford university press
6.
Hiligsmann M, Gathon HJ, Bruyere O, Ethgen O, Rabenda V, Reginster JY (2010) Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 13:394–401CrossRefPubMed
7.
Mobley LR, Hoerger TJ, Wittenborn JS, Galuska DA, Rao JK (2006) Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making 26:194–206CrossRefPubMed
8.
Mueller D, Weyler E, Gandjour A (2008) Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis. Pharmacoeconomics 26:513–536CrossRefPubMed
9.
Nayak S, Roberts MS, Greenspan SL (2011) Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med 155:751–761CrossRefPubMedCentralPubMed
10.
Si L, Winzenberg TM, Palmer AJ (2014) A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int 25:51–60CrossRefPubMed
11.
Kanis JA, Hiligsmann M (2014) The application of health technology assessment in osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism
12.
Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6:1–146CrossRefPubMed
13.
Kingkaew P, Maleewong U, Ngarmukos C, Teerawattananon Y (2012) Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis. Value Health 15:S20–S28CrossRefPubMed
14.
NICE (2012) Osteoporosis: assessing the risk of fragility fracture. NICE clinical guideline. National Clinical Guideline Centre, Manchester
15.
Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB (2012) Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Med Decis Making 32:733–743CrossRefPubMed
16.
China Center for Health Economic Research (2011) China Guidelines for Pharmacoeconomic Evaluations. Beijing
17.
Magee DJ, Zachazewski JE, Quillen WS (2007) Scientific foundations and principles of practice in musculoskeletal rehabilitation. Elsevier Health Sciences
18.
Spiegelhalter DJ, Abrams KR, Myles JP (2004) Bayesian approaches to clinical trials and health-care evaluation. John Wiley & Sons
19.
Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936CrossRefPubMed
20.
RACGP (2010) Clinical guideline for the prevention and treatment of osteoporosis in postmenopausal women and older men. The Royal Australian College of General Practitioners, South Melbourne
21.
Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15CrossRefPubMed
22.
Jonsson B, Kanis J, Dawson A, Oden A, Johnell O (1999) Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int 10:193–199CrossRefPubMed
23.
Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C (2003) Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33:301–307CrossRefPubMed
24.
Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47CrossRefPubMed
25.
Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3–S13CrossRefPubMed
26.
Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM (2006) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28:236–242CrossRefPubMed
27.
Cheng T-T, Yu S-F, Hsu C-Y, Chen S-H, Su BY-J, Yang T-S (2013) Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines. Clin Ther 35:1005–1015CrossRefPubMed
28.
Zhang ZQ, Ho SC, Chen ZQ, Zhang CX, Chen YM (2014) Reference values of bone mineral density and prevalence of osteoporosis in Chinese adults. Osteoporos Int 25:497–507CrossRefPubMed
29.
Ministry of Health, P.R. China (2012) China public health statistical yearbook. Peking Union Medical College Publishing House, Beijing
30.
Wang J, Wang Y, Liu WD, Wang F, Yin ZS (2014) Hip fractures in Hefei, China: the Hefei osteoporosis project. J Bone Miner Metab 32:206–214CrossRefPubMed
31.
32.
Lofthus CM, Frihagen F, Meyer HE, Nordsletten L, Melhuus K, Falch JA (2008) Epidemiology of distal forearm fractures in Oslo, Norway. Osteoporos Int 19:781–786CrossRefPubMed
33.
Melton LJ 3rd, Thamer M, Ray NF, Chan JK, Chesnut CH 3rd, Einhorn TA, Johnston CC, Raisz LG, Silverman SL, Siris ES (1997) Fractures attributable to osteoporosis: report from the national osteoporosis foundation. J Bone Miner Res 12:16–23CrossRefPubMed
34.
Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739CrossRefPubMed
35.
Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fract Interv Trial Res Group Lancet 348:1535–1541
36.
Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280:2077–2082CrossRefPubMed
37.
Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818CrossRefPubMed
38.
Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928CrossRefPubMed
39.
Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513–521CrossRef
40.
41.
Qu B, Ma Y, Yan M, Wu HH, Fan L, Liao DF, Pan XM, Hong Z (2014) The economic burden of fracture patients with osteoporosis in western China. Osteoporos Int 25:1853–1860CrossRefPubMed
42.
Wu M (2011) Research on the development of nursing home care: demand and supply [in Chinese]. Shandong University, Jinan
43.
Liu Y, Yu D, Xu Z (2004) Health survey of 300 nursing home residents [in Chinese]. Chin J Geriatr 23:51
44.
45.
Sun S, Chen J, Johannesson M, Kind P, Xu L, Zhang Y, Burstrom K (2011) Population health status in china: EQ-5D results, by age, sex and socio-economic status, from the national health services survey 2008. Qual Life Res 20:309–320CrossRefPubMedCentralPubMed
46.
Si L, Winzenberg TM, de Graaff B, Palmer AJ (2014) A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions. Osteoporosis international
47.
Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA (2004) Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 20(Suppl 1):S27–S40CrossRefPubMed
48.
Eddy DM, Schlessinger L (2003) Validation of the Archimedes diabetes model. Diabetes Care 26:3102–3110CrossRefPubMed
49.
Hiligsmann M, Ethgen O, Bruyere O, Richy F, Gathon HJ, Reginster JY (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12:687–696CrossRefPubMed
50.
Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674CrossRefPubMed
51.
Kung AW, Lee KK, Ho AY, Tang G, Luk KD (2007) Ten-year risk of osteoporotic fractures in postmenopausal Chinese women according to clinical risk factors and BMD T-scores: a prospective study. J Bone Miner Res Off J Am Soc Bone Miner Res 22:1080–1087CrossRef
52.
Park C, Ha YC, Jang S, Jang S, Yoon HK, Lee YK (2011) The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab 29:744–751CrossRefPubMed
53.
54.
Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD (2012) Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Making 32:722–732CrossRefPubMed
55.
Hiligsmann M, Boonen A, Rabenda V, Reginster JY (2012) The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 12:159–166CrossRefPubMed
56.
Hiligsmann M, Rabenda V, Bruyère O, Reginster J-Y (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96:170–177CrossRefPubMed
57.
Schwenkglenks M, Lippuner K (2007) Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporos Int 18:1481–1491CrossRefPubMed
58.
Mueller D, Gandjour A (2008) Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women. Appl Health Econ Health Policy 6:113–135CrossRefPubMed
59.
Nshimyumukiza L, Durand A, Gagnon M et al (2013) An economic evaluation: simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures. J Bone Miner Res 28:383–394CrossRefPubMedCentralPubMed
60.
Pro T (2006) User’s manual,(2006). TreeAge Software. Inc
61.
Weinstein MC (2006) Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 24:1043–1053CrossRefPubMed
62.
Hagen G, Wisløff T, Falch J, Lofthus C, Frihagen F, Wensaas K-A, Granum L, Nevjar J, Kristiansen I (2011) Efficacy and cost-effectiveness of alendronate for the prevention of fractures in postmenopausal women in Norway. Norwegian Knowledge Centre for the Health Services
63.
Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (2007) A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29:1548–1558CrossRefPubMed
64.
Christensen PM, Brixen K, Gyrd-Hansen D, Kristiansen IS (2005) Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 96:387–396CrossRefPubMed
65.
Lewiecki EM, Gordon CM, Baim S et al (2008) International society for clinical densitometry 2007 adult and pediatric official positions. Bone 43:1115–1121CrossRefPubMed
66.
NOF (2010) Clinician’s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington
67.
Yu EW, Finkelstein JS (2012) Bone density screening intervals for osteoporosis: one size does not fit all. JAMA 307:2591–2592CrossRefPubMed
68.
Gourlay ML, Preisser JS, Lui LY, Cauley JA, Ensrud KE (2012) BMD screening in older women: initial measurement and testing interval. J Bone Miner Res 27:743–746CrossRefPubMedCentralPubMed
69.
Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui L-Y, Ransohoff DF, Cauley JA, Ensrud KE (2012) Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med 366:225–233CrossRefPubMedCentralPubMed
70.
Weinstein MC (1980) Estrogen use in postmenopausal women—costs, risks, and benefits. N Engl J Med 303:308–316CrossRefPubMed
71.
Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices–modeling studies. Value Health 6:9–17CrossRefPubMed
72.
73.
Chen XF, Li XL, Zhang H, Liu GJ (2014) Were you identified to be at high fracture risk by FRAX(R) before your osteoporotic fracture occurred? Clin Rheumatol 33:693–698CrossRefPubMed
74.
Zhang Z, Ou Y, Sheng Z, Liao E (2014) How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women. Endocrine 45:195–197CrossRefPubMedCentralPubMed
75.
Mount H (2007) Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 30:1638–1646CrossRef
76.
Palmer AJ, Clarke P, Gray A et al (2013) Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health 16:670–685CrossRefPubMed
77.
Brown JB, Palmer AJ, Bisgaard P, Chan W, Pedula K, Russell A (2000) The Mt. Hood challenge: cross-testing two diabetes simulation models. Diabetes Res Clin Prac 50(Suppl 3):S57–S64CrossRef
Metadaten
Titel
Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model
verfasst von
L. Si
T. M. Winzenberg
Q. Jiang
A. J. Palmer
Publikationsdatum
01.05.2015
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 5/2015
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-014-2999-4

Weitere Artikel der Ausgabe 5/2015

Osteoporosis International 5/2015 Zur Ausgabe

Original Article

Bone mineral density in patients with symptoms suggestive of spondyloarthritis

Short Communication

Can vitamin D metabolite measurements facilitate a “treat-to-target” paradigm to guide vitamin D supplementation?

Original Article

Infant dietary patterns and bone mass in childhood: the Generation R Study

Editorial

Bisphosphonate therapy: how long is long enough?

Original Article

Plasma dimethylglycine, nicotine exposure and risk of low bone mineral density and hip fracture: the Hordaland Health Study

Original Article

Association between low C-peptide and low lumbar bone mineral density in postmenopausal women without diabetes

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise